124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
12 citations
,
June 2020 in “Journal of The American Academy of Dermatology” Platelet-rich plasma is tolerable for lichen planopilaris and doesn't worsen the condition, but its effectiveness is unclear.
2 citations
,
May 2023 in “Life” Plumbagin may help protect cells, reduce inflammation, and has potential for treating various diseases, but more research is needed.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
4 citations
,
October 2022 in “Current Urology” Platelet-rich plasma shows promise in reducing pain for bladder pain syndrome.
December 2025 in “International Journal of Pharmacology” iPSC-derived artificial platelets show promise for consistent and effective regenerative therapies.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
July 2022 in “British Journal of Dermatology” 57 citations
,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
15 citations
,
January 2014 in “Medicinal chemistry” Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
33 citations
,
October 2013 in “Journal of The American Academy of Dermatology” Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.
21 citations
,
January 2021 in “Frontiers in Pharmacology” Thiopurines help treat IBD but require genetic testing to avoid side effects.
70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
April 2024 in “Journal of pharmacy & pharmacognosy research” A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
4 citations
,
October 2019 in “Acta Médica Costarricense” More research is needed to standardize and prove the effectiveness of platelet-rich plasma treatments.
1 citations
,
January 2020 in “Seoul National University Open Repository (Seoul National University)” PDE3 inhibitor may help treat hair loss by promoting hair growth.
6 citations
,
July 2020 in “The Kaohsiung Journal of Medical Sciences” Inhibiting the PI3K/Akt pathway may help prevent radiation-induced liver injury.
6 citations
,
August 2017 in “Physiological Research” Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
Targeting the PGI2 pathway may help heal diabetic foot ulcers.
1 citations
,
April 2020 in “Journal of The European Academy of Dermatology and Venereology” Drugs like PDEI may help hair disorders like AGA.
October 2025 in “International Journal of Dermatology” JAK inhibitors may help treat certain types of hair loss, but more research is needed.
January 2025 in “Biochemical Pharmacology” Peficitinib can turn human fibroblasts into cells that help grow hair.
August 2025 in “International Journal of Scientific Research” PRP is a promising alternative for alopecia areata due to its safety and patient satisfaction.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
297 citations
,
December 2005 in “Journal of controlled release” P-SLN nanoparticles effectively deliver podophyllotoxin to the skin.